Watchlist · 75/100Sep 3, 9:24 AM EDT
AbbVie Finalizes $10.9B Takeover of Apogee Therapeutics
ABBVAPGE
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, marking its largest bolt-on deal since 2019. The acquisition, initially reported in June, is expected to bolster AbbVie's pipeline, likely with Apogee's respiratory and immunology asset…
- ▹Large M&A validates Apogee's platform and pipeline, but single-asset focus and early-stage data cap upside.
- ▹AbbVie's commercial infrastructure and manufacturing expertise mitigate risks, but regulatory and clinical execution remain key.
Neutral · 60/100Sep 3, 10:16 AM EDT
AbbVie's Investigational Myeloma Drug Meets Primary Endpoint in Phase 3 Trial
ABBV
AbbVie (ABBV) announced that its experimental therapy etentamig succeeded in a Phase 3 trial (CERVINO) for heavily pretreated multiple myeloma patients. The positive topline data could support regulatory filings and expand AbbVie's oncology portfolio, potentia…
- ▹Positive Phase 3 data for etentamig in heavily pretreated multiple myeloma, but regulatory path still uncertain.
- ▹AbbVie is a large pharma with commercial infrastructure, but this is a single asset in a competitive space.
High Risk · 47/100Sep 3, 10:08 AM EDT
Wall Street's Least-Shorted Stocks: A Safe Haven Watchlist
PGHDGEBA
A new screen reveals 196 mid- to mega-cap stocks with short interest between 1% and 2%, indicating low bearish sentiment. Notable names include PG, HD, GE, and BA, which may signal stability or limited downside risk for investors.
- ▹No specific FDA or regulatory catalysts; generic large-cap stocks with no biotech-specific news.
- ▹Low short interest is a market sentiment metric, not a fundamental driver for biotech investment.